Exploring The Impact Of Radiographic Progressive Disease And First Subsequent Therapy On Health State Utility Values

October 18, 2018 Danielle Twigg

Maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib, following response to platinum-based chemotherapy, significantly extends progression-free survival (PFS) and time to first subsequent treatment or death in patients with gBRCAm PSROC. We evaluate the impact of radiographic progression and subsequent therapy on health state utility values (HSUVs) of patients in the ENGOT-OV21/SOLO2 clinical study.

Authors: Sackeyfio A, Santi I, Friedlander M

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
How Much Is Your Life Worth? Defining What The Willingness To Pay For A QALY Is and Should Be
How Much Is Your Life Worth? Defining What The Willingness To Pay For A QALY Is and Should Be

Next Article
Danish Medicine Council Process Of Assessing New Hospital Medicines – First Year Of Implementation
Danish Medicine Council Process Of Assessing New Hospital Medicines – First Year Of Implementation